Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials.
Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials.
复制标题
DOI：
10.1177/20406223231204727
复制
发表时间：
2023
影响因子：
3.5
通讯作者：
Bauer BA
中科院分区：
文献类型：
--
作者：
Yang J;Lim KH;Lim KT;Woods JT;Mohabbat AB;Wahner-Roedler DL;Ganesh R;Bauer BA
Complementary and alternative medicine (CAM) interventions are growing in popularity as possible treatments for long COVID symptoms. However, comprehensive analysis of current evidence in this setting is still lacking. This study aims to review existing published studies on the use of CAM interventions for patients experiencing long COVID through a systematic review. Systematic review of randomized controlled trials (RCTs). A comprehensive electronic literature search was performed in multiple databases and clinical trial registries from September 2019 to January 2023. RCTs evaluating efficacy and safety of CAM for long COVID were included. Methodological quality of each included trial was appraised with the Cochrane ‘risk of bias’ tool. A qualitative analysis was conducted due to heterogeneity of included studies. A total of 14 RCTs with 1195 participants were included in this review. Study findings demonstrated that CAM interventions could benefit patients with long COVID, especially those suffering from neuropsychiatric disorders, olfactory dysfunction, cognitive impairment, fatigue, breathlessness, and mild-to-moderate lung fibrosis. The main interventions reported were self-administered transcutaneous auricular vagus nerve stimulation, neuro-meditation, dietary supplements, olfactory training, aromatherapy, inspiratory muscle training, concurrent training, and an online breathing and well-being program. CAM interventions may be effective, safe, and acceptable to patients with symptoms of long COVID. However, the findings from this systematic review should be interpreted with caution due to various methodological limitations. More rigorous trials focused on CAM for long COVID are warranted in the future.
登录
查看更多内容
影响因子：
12.4
作者：
Mantovani, Alberto;Morrone, Maria Concetta;Patrono, Carlo;Santoro, M. Gabriella;Schiaffino, Stefano;Remuzzi, Giuseppe;Bussolati, Giovanni
通讯作者：
Bussolati, Giovanni
DOI：
10.26355/eurrev_202106_26059
发表时间：
2021-01-01
影响因子：
3.3
作者：
D'Ascanio, L.;Vitelli, F.;Di Stadio, A.
通讯作者：
Di Stadio, A.
影响因子：
0.9
作者：
Hong, Quan Nha;Fabregues, Sergi;Pluye, Pierre
通讯作者：
Pluye, Pierre
影响因子：
5.1
作者：
Brussow, Harald;Timmis, Kenneth
通讯作者：
Timmis, Kenneth
影响因子：
76.2
作者：
Philip, Keir E. J.;Owles, Harriet;McVey, Stephanie;Pagnuco, Tanja;Bruce, Katie;Brunjes, Harry;Banya, Winston;Mollica, Jenny;Lound, Adam;Zumpe, Suzi;Abrahams, Amiad M.;Padmanaban, Vijay;Hardy, Thomas H.;Lewis, Adam;Lalvani, Ajit;Elkin, Sarah;Hopkinson, Nicholas S.
通讯作者：
Hopkinson, Nicholas S.